Brigatinib received its first global approval in 2017 due to the robust efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) 18, 19. The gene discussed is ALK; the disease is non-small cell lung carcinoma.